News and Views

The Psychedelic Renaissance: Is Psychiatry on the Verge of a Breakthrough?

7 min read

Two glowing mushrooms, one purple and one blue, among swirling green and blue shapes
Illustration by Hannah Russak

A treatment once associated with counterculture and recreational drug use may soon find a place in modern psychiatry. In 2026, promising results from late-stage clinical trials brought psilocybin (SY-luh-SY-bin) one step closer to potential FDA approval for treatment-resistant depression. Yet other recent studies have raised questions about how effective these treatments actually are.

This renewed scientific interest, often called the psychedelic renaissance, has brought substances like psilocybin, the psychoactive compound found in certain mushrooms, back into mainstream psychiatric research after decades of controversy. Researchers are particularly interested in whether psychedelics could offer new treatment options for people with depression who have not responded to conventional antidepressants. Unlike medications that are generally taken daily, psilocybin is being investigated as a treatment that might produce lasting improvements following just one or two supervised dosing sessions. Scientists believe its effects may involve changes in how different regions of the brain communicate, as well as neuroplasticity, the brain’s ability to reorganize connections between neurons.1

But despite growing excitement, researchers are still trying to determine how much of the observed improvement can be attributed to psilocybin itself. In March 2026, a randomized clinical trial published in JAMA Psychiatry by Mertens et al.2 offered a closer look at this question. The study, called the EPISODE trial, investigated whether psilocybin, administered alongside psychotherapy, could reduce symptoms in individuals with treatment-resistant depression.

The researchers recruited 144 adults between the ages of 25 and 64 from two clinical centers in Germany. Participants had treatment-resistant major depression and were required to discontinue ongoing antidepressant medication before dosing. They were randomly assigned to four treatment sequences involving two dosing sessions, six weeks apart. During the first session, participants received either 25 mg of psilocybin, a lower 5 mg dose, or 100 mg of nicotinamide, a form of vitamin B3 used as a comparison treatment. All participants received structured psychotherapeutic support and were assigned to receive at least one 25 mg dose of psilocybin during the study. By comparing these groups, the researchers hoped to determine whether a higher dose of psilocybin could produce greater improvements in depression than a lower dose or comparison treatment.2

The study’s primary outcome was treatment response after six weeks, defined as at least a 50% reduction in symptoms on the 17-item Hamilton Rating Scale for Depression, a commonly used clinical measure of depression severity. Of the 47 participants receiving 25 mg of psilocybin included in the primary analysis, 17% met the criteria for treatment response. In comparison, 12.5% of those receiving the lower dose and 10.6% of those receiving nicotinamide met the same criteria. Although the response rate was highest in the 25-mg group, the difference between that group and the nicotinamide group was not statistically significant (p = .19).2

At first, these findings might seem disappointing. However, the researchers also examined how much participants’ depression scores changed on average, rather than simply whether they met the threshold for treatment response. On this measure, participants receiving 25 mg of psilocybin showed greater reductions in depressive symptoms than those receiving nicotinamide, with an estimated difference of 4.60 points on the Hamilton scale after six weeks. Although this difference was statistically significant in an exploratory analysis (p < 0.001), the trial’s statistical analysis plan limited its interpretation because the primary outcome had not reached significance.2

How can a treatment significantly reduce depressive symptoms without significantly improving treatment response? The answer comes down to how researchers define success. Average symptom reduction measures how much depression severity changes across a group of participants, while treatment response requires individuals to improve by a predetermined amount. A treatment could therefore produce measurable improvements across a group without enough participants reaching the threshold to be classified as responders. The EPISODE trial illustrates why these two outcomes, although related, do not necessarily tell the same story.

Another interesting finding was how quickly participants appeared to respond. Just one week after treatment, 34% of participants receiving 25 mg of psilocybin met the criteria for treatment response, compared with 6.4% of those receiving nicotinamide and 10.4% receiving the lower dose.2 This early difference suggests that psilocybin may produce relatively rapid antidepressant effects. However, by the six-week assessment, response rates in the 25-mg group had declined, raising questions about how long these improvements last and whether additional treatment sessions are necessary.

The study also examined the effects of a second dosing session, administered six weeks after the first. By the end of the 12-week study, all treatment groups had been assigned to receive at least one 25-mg dose of psilocybin. Although depressive symptoms improved across groups, the researchers did not find evidence of an additional benefit from receiving two 25-mg doses rather than one during the study period.2 These findings suggest that determining the most effective dosing schedule may be just as important as establishing whether psilocybin works in the first place. However, the absence of follow-up beyond 12 weeks makes it difficult to draw conclusions about long-term effectiveness.

Safety was another important consideration. While most participants tolerated the treatment, psilocybin was associated with adverse events, particularly around the time of administration. Suicidal ideation was reported following 4% of the 25-mg dosing sessions, compared with 1-2% of comparison dosing sessions, although worsening of suicidal ideation from baseline was similar across treatment groups. Two serious adverse reactions were considered related to the 25-mg dose, including one case of hallucinogen persisting perception disorder, a condition involving persistent perceptual disturbances.2 These findings highlight the importance of careful monitoring, particularly when treating individuals already experiencing severe psychiatric symptoms.

The EPISODE trial adds an important perspective to a field that has recently received considerable attention for its promising results. In July 2026, Compass Pathways reported encouraging six-month findings from a Phase 3 clinical trial of COMP360, its synthetic psilocybin formulation, for treatment-resistant depression.3 Unlike psilocybin extracted from mushrooms, COMP360 is manufactured under controlled conditions but contains the same active compound. In November, the company announced that it was nearing completion of its application for FDA approval.4 However, these findings cannot be directly compared with the EPISODE results because the trials used different treatment protocols, outcome measures, and definitions of clinical improvement. The Compass Pathways findings are also company-reported, while the EPISODE results have been published in a peer-reviewed journal.

Taken together, these developments illustrate both the promise and uncertainty surrounding psychedelic-assisted treatment. The EPISODE trial found exploratory evidence that psilocybin may reduce depression severity, but its failure to meet the primary outcome demonstrates why promising results require careful interpretation. The study also highlights important challenges in psychedelic research, particularly the difficulty of keeping participants unaware of which treatment they received. Because psilocybin produces noticeable changes in perception and consciousness, participants may recognize when they have received the drug, potentially influencing their expectations and reported improvements.1 Future research will need to address these limitations while investigating which patients are most likely to benefit, how long improvements last, and whether different treatment schedules can produce more consistent results.

The psychedelic renaissance may eventually change how depression is treated, but the EPISODE trial serves as a reminder that scientific progress is rarely straightforward. A treatment can show encouraging effects without providing definitive evidence of efficacy. As psilocybin moves closer to potential clinical use, understanding that distinction will be essential in determining whether psychedelics can deliver on their promise and become a reliable part of psychiatric care.

References

  1. Siegel, J. S., Liston, C., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026). The science of psychedelic medicine. Nature Medicine, 32, 449–462. https://doi.org/10.1038/s41591-025-04194-5
  2. Mertens, L. J., Koslowski, M., Betzler, F., Brand, M., Evens, R., Kärtner, L., Jungaberle, A., Jungaberle, H., Majić, T., Schmitz, C. N., Ströhle, A., Scharf, D., Spangemacher, M., Wolff, M., Assadi, Z., Bahri, S., Becher, L., Färber, L. V., Kirchen, N., . . . Gründer, G. (2026). Efficacy and safety of psilocybin in treatment-resistant major depression: The EPISODE randomized clinical trial. JAMA Psychiatry, 83(5), 448–460. https://doi.org/10.1001/jamapsychiatry.2026.0132
  3. Compass Pathways. (2026a, July 7). Compass Pathways announces six-month data from second Phase 3 trial confirming rapid and durable profile. https://ir.compasspathways.com/News–Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/default.aspx
  4. Compass Pathways. (2026b, November 3). Compass Pathways announces third quarter 2026 financial results and business highlights. https://ir.compasspathways.com/News–Events-/news/news-details/2026/Compass-Pathways-Announces-Third-Quarter-2026-Financial-Results-and-Business-Highlights/default.aspx

Spotted an error? Email [email protected] from your Wesleyan account.

More from Research & Reviews

Literature Reviews

Safety or Sabotage? Exploring the Call of the Void

If you have ever stood at the ledge of a balcony, eyeing the streetscape below, or waited at the edge of a train platform with the hum of commuters at your back, you may have felt a sudden, inexplicable urge to leap. This experience is not uncommon.

Literature Reviews

The Puzzle of Predicting Protein Function Continues: AlphaFold and Beyond

Amino acids, commonly referred to as the “building blocks of life”, are not merely the brick and mortar of all living things.1,2 These twenty molecules combine to form all of the proteins that make up organisms.2 There are proteins that shuttle molecules across membranes and others that prevent the water inside cells from freezing.